Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial

Trial Profile

Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary)
  • Indications Ependymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 Planned number of patients changed from 46 to 35.
    • 23 Oct 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2018, as reported by ClinicalTrials.gov record.
    • 12 Aug 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top